0.6553
price up icon1.93%   0.0129
 
loading
Schlusskurs vom Vortag:
$0.6424
Offen:
$0.6646
24-Stunden-Volumen:
4.54M
Relative Volume:
0.66
Marktkapitalisierung:
$145.49M
Einnahmen:
$2.04M
Nettoeinkommen (Verlust:
$-43.21M
KGV:
-3.1703
EPS:
-0.2067
Netto-Cashflow:
$-105.93M
1W Leistung:
+13.98%
1M Leistung:
-41.01%
6M Leistung:
-73.60%
1J Leistung:
-51.50%
1-Tages-Spanne:
Value
$0.6452
$0.7063
1-Wochen-Bereich:
Value
$0.5601
$0.7063
52-Wochen-Spanne:
Value
$0.5469
$2.93

Humacyte Inc Stock (HUMA) Company Profile

Name
Firmenname
Humacyte Inc
Name
Telefon
919-313-9633
Name
Adresse
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Name
Mitarbeiter
184
Name
Twitter
Name
Nächster Verdiensttermin
2026-03-27
Name
Neueste SEC-Einreichungen
Name
HUMA's Discussions on Twitter

Compare HUMA vs VRTX, REGN, ARGX, ALNY, INSM

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
HUMA icon
HUMA
Humacyte Inc
0.6553 142.63M 2.04M -43.21M -105.93M -0.2067
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
433.59 111.45B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
762.90 80.54B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
747.75 46.32B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
330.75 42.29B 3.71B 313.75M 465.38M 2.2571
INSM icon
INSM
Insmed Inc
164.04 35.01B 606.42M -1.28B -997.58M -6.403

Humacyte Inc Stock (HUMA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-08-27 Eingeleitet Barclays Overweight
2025-05-14 Fortgesetzt H.C. Wainwright Buy
2024-12-20 Bestätigt H.C. Wainwright Buy
2023-12-11 Eingeleitet H.C. Wainwright Buy
2023-08-14 Hochstufung Piper Sandler Underweight → Neutral
2023-06-22 Eingeleitet Cantor Fitzgerald Overweight
2022-05-16 Herabstufung Piper Sandler Overweight → Underweight
2021-10-29 Eingeleitet Cowen Outperform
2021-09-24 Eingeleitet Oppenheimer Outperform
2021-09-22 Eingeleitet BTIG Research Buy
2021-09-16 Eingeleitet Piper Sandler Overweight
Alle ansehen

Humacyte Inc Aktie (HUMA) Neueste Nachrichten

pulisher
02:55 AM

Why BTIG cut its target on Humacyte (HUMA) but kept a bullish view on the bigger opportunity - MSN

02:55 AM
pulisher
Apr 05, 2026

HUMA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 05, 2026
pulisher
Apr 05, 2026

Humacyte, Inc. (HUMA) stock sinks as market gains: Here's why - msn.com

Apr 05, 2026
pulisher
Apr 05, 2026

What is the long term forecast for Humacyte Inc stock2026 PostEarnings & Capital Protection Trading Alerts - baoquankhu1.vn

Apr 05, 2026
pulisher
Apr 04, 2026

HUMA Should I Buy - Intellectia AI

Apr 04, 2026
pulisher
Apr 03, 2026

Humacyte targets over 200 hospital access points for Symvess as VAC approvals surge and cost cuts extend cash runway - MSN

Apr 03, 2026
pulisher
Apr 02, 2026

Surprises Report: Should I average down on Humacyte Inc stock2026 Catalysts & Comprehensive Market Scan Insights - baoquankhu1.vn

Apr 02, 2026
pulisher
Apr 02, 2026

HC Wainwright Issues Positive Forecast for Humacyte Earnings - MarketBeat

Apr 02, 2026
pulisher
Apr 02, 2026

Humacyte, Inc. (HUMA) stock price, news, quote and history - Yahoo Finance UK

Apr 02, 2026
pulisher
Apr 01, 2026

Humacyte, Inc. (HUMA) Shares Decline Despite Overall Market Rise: The Reason Explained - Bitget

Apr 01, 2026
pulisher
Apr 01, 2026

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why - Yahoo Finance Singapore

Apr 01, 2026
pulisher
Mar 31, 2026

HUMA: Benchmark Downgrades Humacyte with Lowered Price Target | - GuruFocus

Mar 31, 2026
pulisher
Mar 31, 2026

Benchmark Reaffirms "Speculative Buy" Rating for Humacyte (NASDAQ:HUMA) - MarketBeat

Mar 31, 2026
pulisher
Mar 31, 2026

Benchmark Downgrades Humacyte to Speculative Buy From Buy, Adjusts Price Target to $1 From $11 - moomoo.com

Mar 31, 2026
pulisher
Mar 31, 2026

Earnings Miss: Can Humacyte Inc sustain its profitabilityPortfolio Growth Summary & Low Risk High Win Rate Picks - baoquankhu1.vn

Mar 31, 2026
pulisher
Mar 31, 2026

This Rockwell Automation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Sahm

Mar 31, 2026
pulisher
Mar 30, 2026

Aug Macro: Does Humacyte Inc Equity Warrant have declining or rising EPS2026 PreEarnings & Weekly Watchlist of Top Performers - baoquankhu1.vn

Mar 30, 2026
pulisher
Mar 30, 2026

Piper Sandler Cuts Humacyte (NASDAQ:HUMA) Price Target to $1.00 - MarketBeat

Mar 30, 2026
pulisher
Mar 30, 2026

Piper Sandler cuts Humacyte stock price target on weak sales - Investing.com UK

Mar 30, 2026
pulisher
Mar 30, 2026

Piper Sandler cuts Humacyte stock price target on weak sales By Investing.com - Investing.com Canada

Mar 30, 2026
pulisher
Mar 30, 2026

TD Cowen Has Lowered Expectations for Humacyte (NASDAQ:HUMA) Stock Price - MarketBeat

Mar 30, 2026
pulisher
Mar 30, 2026

TD Cowen lowers Humacyte stock price target to $1 on launch concerns - investing.com

Mar 30, 2026
pulisher
Mar 30, 2026

TD Cowen lowers Humacyte stock price target to $1 on launch concerns By Investing.com - Investing.com South Africa

Mar 30, 2026
pulisher
Mar 30, 2026

Piper Sandler Maintains Humacyte(HUMA.US) With Hold Rating, Cuts Target Price to $1 - moomoo.com

Mar 30, 2026
pulisher
Mar 30, 2026

TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Cuts Target Price to $1 - moomoo.com

Mar 30, 2026
pulisher
Mar 29, 2026

Humacyte, Inc. (HUMA) reports Q4 loss, misses revenue estimates - MSN

Mar 29, 2026
pulisher
Mar 29, 2026

Why BTIG Cut Its Target on Humacyte (HUMA) but Kept a Bullish View on the Bigger Opportunity - Yahoo Finance

Mar 29, 2026
pulisher
Mar 29, 2026

Smart Money: Does Humacyte Inc Equity Warrant have declining or rising EPSPortfolio Update Summary & Stock Market Timing Techniques - baoquankhu1.vn

Mar 29, 2026
pulisher
Mar 28, 2026

5 Penny Stocks with Potential to Rise 1000 Percent - Insider Monkey

Mar 28, 2026
pulisher
Mar 27, 2026

Humacyte earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada

Mar 27, 2026
pulisher
Mar 27, 2026

Humacyte misses revenue target despite in-line earnings By Investing.com - ca.investing.com

Mar 27, 2026
pulisher
Mar 27, 2026

Humacyte 10-K: Revenue $2.04M, EPS $(0.26) - TradingView

Mar 27, 2026
pulisher
Mar 27, 2026

Humacyte (NASDAQ: HUMA) details Symvess FDA approval, launch and ATEV pipeline in 10-K - Stock Titan

Mar 27, 2026
pulisher
Mar 27, 2026

Humacyte secures $1.48M Symvess purchase commitment in Saudi Arabia - MSN

Mar 27, 2026
pulisher
Mar 27, 2026

Humacyte (NASDAQ:HUMA) Given "Buy" Rating at D. Boral Capital - MarketBeat

Mar 27, 2026
pulisher
Mar 27, 2026

Humacyte shares see BTIG price target cut to $3 on lower sales outlook - Investing.com UK

Mar 27, 2026
pulisher
Mar 27, 2026

Humacyte shares see BTIG price target cut to $3 on lower sales outlook By Investing.com - Investing.com India

Mar 27, 2026
pulisher
Mar 27, 2026

Humacyte (NASDAQ:HUMA) Issues Earnings Results - MarketBeat

Mar 27, 2026
pulisher
Mar 27, 2026

BTIG Research Lowers Humacyte (NASDAQ:HUMA) Price Target to $3.00 - MarketBeat

Mar 27, 2026
pulisher
Mar 27, 2026

Humacyte Q4 2025 earnings preview - MSN

Mar 27, 2026
pulisher
Mar 27, 2026

Humacyte Q4 Earnings Call Highlights - MarketBeat

Mar 27, 2026
pulisher
Mar 27, 2026

Earnings call transcript: Humacyte Q4 2025 revenue misses forecast By Investing.com - Investing.com Australia

Mar 27, 2026
pulisher
Mar 27, 2026

Earnings call transcript: Humacyte Q4 2025 revenue misses forecast - Investing.com

Mar 27, 2026
pulisher
Mar 27, 2026

HUMA: Symvess adoption grows with strong clinical data, improved pricing, and expanding global reach - TradingView

Mar 27, 2026
pulisher
Mar 27, 2026

Humacyte Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2026
pulisher
Mar 27, 2026

Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Mar 27, 2026
pulisher
Mar 27, 2026

Humacyte earnings matched, revenue fell short of estimates - Investing.com

Mar 27, 2026

Finanzdaten der Humacyte Inc-Aktie (HUMA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Humacyte Inc-Aktie (HUMA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Dougan Brady W
Director
Aug 18 '25
Sale
1.83
549,360
1,005,329
1,691,685
Dougan Brady W
Director
Aug 20 '25
Sale
1.58
591,685
934,862
0
Niklason Laura E
President, CEO and Director
Aug 19 '25
Sale
1.63
1,100,000
1,793,000
591,685
Niklason Laura E
President, CEO and Director
Aug 18 '25
Sale
1.83
549,360
1,005,329
1,691,685
Niklason Laura E
President, CEO and Director
Aug 20 '25
Sale
1.58
591,685
934,862
0
$49.55
price down icon 1.90%
$28.34
price up icon 1.08%
$47.79
price down icon 1.05%
$91.15
price up icon 0.08%
ONC ONC
$311.43
price up icon 0.93%
$163.18
price down icon 1.52%
Kapitalisierung:     |  Volumen (24h):